Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
International Journal of Chronic Obstructive Pulmonary Disease|September 8, 2022
Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL TrialReynold A Panettieri, Carlos A Camargo, Tariq Cheema, et al.
ERJ Open Research|June 10, 2021
INTREPID: single- <i>versus</i> multiple-inhaler triple therapy for COPD in usual clinical practiceDavid M G Halpin, Sally Worsley, Afisi S Ismaila, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 1, 2022
Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID TrialDavid M G Halpin, Robyn Kendall, Soham Shukla, et al.
Journal of the American Heart Association|September 14, 2022
Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT TrialMark T Dransfield, Gerard J Criner, David M G Halpin, et al.
Respirology (Carlton, Vic.)|August 15, 2022
Effect of chronic mucus hypersecretion on treatment responses to inhaled therapies in patients with chronic obstructive pulmonary disease: Post hoc analysis of the IMPACT trialPhilip J Thompson, Gerard J Criner, Mark T Dransfield, et al.
Chronic Obstructive Pulmonary Diseases (Miami, Fla.)|December 31, 2021
Higher COPD Assessment Test Score Associated With Greater Exacerbations Risk: A Post Hoc Analysis of the IMPACT TrialByron Thomashow, Marjorie Stiegler, Gerard J Criner, et al.
Respiratory Medicine|December 5, 2022
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysisSamuel Bardsley, Gerard J Criner, David M G Halpin, et al.
European Respiratory Review : an Official Journal of the European Respiratory Society|November 18, 2021
Discordant diagnostic criteria for pneumonia in COPD trials: a reviewRobert A Wise, Mona Bafadhel, Courtney Crim, et al.
American Journal of Respiratory and Critical Care Medicine|March 13, 2020
Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary DiseaseDavid A Lipson, Courtney Crim, Gerard J Criner, et al.
Pageof 2